US Penny Stocks To Watch In November 2024

As the U.S. stock market experiences a resurgence, with major indexes on track for weekly gains and Bitcoin reaching new all-time highs, investors are exploring diverse opportunities to capitalize on these trends. Penny stocks, often representing smaller or newer companies, remain an intriguing option despite their historical connotations. They can offer a unique blend of value and growth potential when supported by strong financial fundamentals, presenting investors with promising avenues for discovering hidden value in lesser-known firms.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.8368	$5.81M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$143.63M	★★★★★★
Better Choice (NYSEAM:BTTR)	$1.7017	$3.25M	★★★★★★
RLX Technology (NYSE:RLX)	$1.78	$2.31B	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.21	$7.6M	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.30	$547.49M	★★★★★★
Puma Biotechnology (NasdaqGS:PBYI)	$2.90	$139.41M	★★★★★★
Zynerba Pharmaceuticals (NasdaqCM:ZYNE)	$1.30	$65.6M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8694	$76.61M	★★★★★☆

Click here to see the full list of 740 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

OptimizeRx (NasdaqCM:OPRX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OptimizeRx Corporation is a digital health technology company that facilitates care-focused engagement among life sciences organizations, healthcare providers, and patients during critical points in the patient care journey, with a market cap of $81.42 million.

Operations: The company generates its revenue primarily from the Internet Software & Services segment, totaling $88.18 million.

Market Cap: $81.42M

OptimizeRx, with a market cap of US$81.42 million, faces challenges typical of penny stocks, including volatility and profitability issues. Despite a satisfactory net debt to equity ratio of 16.7% and short-term assets exceeding liabilities, the company remains unprofitable with losses increasing over five years at 47% annually. Recent financials show a Q3 net loss of US$9.12 million despite revenue growth to US$21.31 million from the previous year’s US$16.33 million. Impairment charges further impact its financial health, while revenue guidance for 2024 is set between US$88-92 million amidst ongoing strategic presentations by management in key forums.

• Unlock comprehensive insights into our analysis of OptimizeRx stock in this financial health report.
• Examine OptimizeRx's earnings growth report to understand how analysts expect it to perform.

Cheetah Mobile (NYSE:CMCM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cheetah Mobile Inc., along with its subsidiaries, provides internet services and artificial intelligence solutions in China, Hong Kong, Japan, and internationally, with a market cap of approximately $137.76 million.

Operations: The company's revenue is derived from its Internet Business segment, which generated CN¥437.24 million, and its AI and Others segment, which brought in CN¥272.59 million.

Market Cap: $137.76M

Cheetah Mobile, with a market cap of US$137.76 million, exemplifies the volatility and challenges associated with penny stocks. Despite being debt-free and having substantial short-term assets (CN¥3.9 billion) covering liabilities, the company remains unprofitable with net losses decreasing to CN¥123.84 million in Q2 2024 from CN¥258.79 million a year ago. Revenue for the same period increased to CN¥187.42 million from CN¥166.95 million last year, yet shareholders faced dilution as outstanding shares grew by 3.1%. The seasoned management team contrasts with an inexperienced board, contributing to ongoing strategic uncertainties.

• Navigate through the intricacies of Cheetah Mobile with our comprehensive balance sheet health report here.
• Evaluate Cheetah Mobile's historical performance by accessing our past performance report.

Nevro (NYSE:NVRO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Nevro Corp. is a medical device company that provides products for patients suffering from chronic pain in the United States and internationally, with a market cap of $158.50 million.

Operations: The company's revenue is derived entirely from its medical products segment, totaling $419.15 million.

Market Cap: $158.5M

Nevro Corp., with a market cap of US$158.50 million, illustrates the complexities of penny stocks in the medical device sector. Despite unprofitability and a negative return on equity, Nevro has reduced net losses over five years by 11.2% annually. The company reported third-quarter sales of US$96.91 million and reaffirmed its full-year revenue guidance between US$400 million to US$405 million for 2024, indicating stable financial management despite challenges. Recent product data publications highlight potential advancements in pain management solutions, yet shareholder dilution persists with shares increasing by 3.5% over the past year amidst high share price volatility.

• Get an in-depth perspective on Nevro's performance by reading our balance sheet health report here.
• Evaluate Nevro's prospects by accessing our earnings growth report.

Key Takeaways

• Embark on your investment journey to our 740 US Penny Stocks selection here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com